Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Nature and Prevalence of Pain in Fabry Disease and Its Response to Enzyme Replacement Therapy—A Retrospective Analysis From the Fabry Outcome Survey

Hoffmann, Bjoern MD*; Beck, Michael PhD; Sunder-Plassmann, Gere PhD; Borsini, Walter MD§; Ricci, Roberta PhD; Mehta, Atul MDon behalf of the FOS European Investigators

doi: 10.1097/AJP.0b013e318074c986
Original Articles

Background Fabry disease is a multisystemic life-threatening lysosomal storage disorder caused by deficiency of α-galactosidase A. Symptoms of the disease may occur in different organs including kidney, heart, and the nervous system.

Objectives To evaluate the nature and prevalence of pain in a large cohort of patients with Fabry disease and to assess the effect of enzyme replacement therapy (ERT) with agalsidase alfa.

Methods Retrospective analysis of the data of 752 patients with Fabry disease (393 females, 353 males) enrolled in the Fabry Outcome Survey, a multicentre database.

Results The prevalence of pain in male patients was 81.4% (females 65.3%). Mean age at onset of pain was 14.8±1.0 year in males (females 19.8±1.4 y). Pain was most frequently reported in the hands (males 76%, females 60%) and feet (males 73%, females 52%), but often affected the whole body. Interference of pain with daily life was higher in females than in males, and was observed predominantly for general activities, mood, and normal work. Fifty-eight percent of the patients were on ERT with agalsidase alfa. At 24 and 36 months after commencement of ERT, pain severity classification shifted towards lower severity (P<0.05). Moreover, after 36 months, “average pain” and “pain now” were significantly reduced (P<0.05).

Conclusions Pain is one of the most prevalent symptoms in Fabry disease with onset early in childhood. ERT with agalsidase alfa significantly reduces pain in this debilitating disorder.

*University Children's Hospital, Heinrich-Heine-University Duesseldorf

Children's Hospital, University of Mainz, Germany

Department of Medicine III, Medical University Vienna, Austria

§Department of Neurology and Psychiatric, University of Florence

Department of Pediatrics, University of Rome, Italy

Royal Free Hospital, Royal Free and University College School of Medicine, University College London, London, UK

Reprints: Bjoern Hoffmann, MD, Department of General Pediatrics, University Children's Hospital, Heinrich-Heine-University, Moorenstr. 5, D-40225 Duesseldorf (e-mail: hoffmann@med.uni-duesseldorf.de).

Received for publication July 11, 2006; accepted April 17, 2007

© 2007 Lippincott Williams & Wilkins, Inc.